IN A SIGNIFICANT breakthrough, researchers based in Germany have uncovered a vital function of the insulin-inhibitory receptor ‘Inceptor,’ which could revolutionise diabetes treatment. Initially identified in 2021 as a suppressor of the insulin signalling pathway, Inceptor has now been found to play a critical role in insulin regulation within beta cells.
The new study reveals that Inceptor not only inhibits insulin sensitivity by blocking the insulin receptor on beta cells but also binds to excess insulin and directs it towards degradation. This function, previously unknown, provides key insights into how beta cells maintain insulin balance and regulate secretion. The team emphasised the significance of the findings, reporting that “this knowledge about Inceptor’s function gives us a deeper understanding of how beta cells regulate their insulin homeostasis.”
Beta cells play a crucial role in producing and secreting insulin, and their dysfunction is a hallmark of diabetes. The study demonstrated that by blocking Inceptor, beta cells could replenish their insulin stores, improve secretion, and avoid cell death. This discovery is particularly promising for treating damaged cells, as it enhances their function and viability.
“Blocking Inceptor could help boost insulin production and protect beta cells, especially in already damaged cells,” explained the authors.
The discovery paves the way for therapies that target Inceptor, offering hope to individuals with Type 2 diabetes. Early intervention could slow disease progression, enhance beta cell resilience, and reduce the risk of complications.
The team is already working to translate their findings into practical treatments. A start-up has been established to develop drugs that inhibit Inceptor, aiming to regenerate or protect beta cells. Preclinical studies are underway to ensure the safety and efficacy of these treatments.
This research marks a vital step towards innovative therapies, bringing new hope to millions affected by diabetes worldwide. “Our goal is to pave the way for clinical trials and thereby contribute to the treatment, and hopefully even the cure, of diabetes,” the group commented.
Reference
Siehler J et al. Inceptor binds to and directs insulin towards lysosomal degradation in β cells. Nat Metab. 2024;DOI:10.1038/s42255-024-01164-y.
